Nanjing Xinbai: It is expected that the net profit will decrease by 77.15% to 78.90% year-on-year in the first half of 2026.

Nanjing New Bai's announcement is expected to have a net profit of 35,120,200 to 38,046,900 yuan in the first half of 2026, a year-on-year decrease of 77.15% to 78.90%. During the reporting period, the decline in sales of the product PROVENGE controlled by Dendreon Pharmaceuticals LLC, a wholly-owned subsidiary of the company's subsidiary Shideng Biotechnology Co., Ltd., reduced Shideng Hong Kong's net profit by approximately 142 million yuan.